The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine
HCV represents a global health problem with ~200 million individuals currently infected, worldwide. With the high cost of antiviral therapies, the global burden of chronic hepatitis C infection (CHCV) infection will be substantially reduced by the development of an effective vaccine for HCV. The fie...
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Frontiers Media S.A.
2017-11-01
|
| Sarja: | Frontiers in Microbiology |
| Aiheet: | |
| Linkit: | http://journal.frontiersin.org/article/10.3389/fmicb.2017.02163/full |